Research programme: respiratory and inflammatory disease therapeutics - Argenta/AstraZeneca/BioFocus

Drug Profile

Research programme: respiratory and inflammatory disease therapeutics - Argenta/AstraZeneca/BioFocus

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argenta; AstraZeneca; BioFocus DPI
  • Developer Argenta; BioFocus DPI
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory tract disorders
  • No development reported Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in United Kingdom
  • 30 Jul 2015 Charles River Laboratories and AstraZeneca extend their collaboration for an additional 5 year period
  • 07 Oct 2014 Preclinical trials in Respiratory tract disorders in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top